Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma

Kyle R Stephens; Megan Wilson; Manting Xu; Jeremy T Gaskins; Gina Genova; Robert C G Martin II

doi:10.3748/wjg.v32.i5.113693

January 27, 2026World Journal of GastroenterologyOpen Access

Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

M2BPGi serves as a strong indicator of recurrence in hepatocellular carcinoma after hepatectomy, with potential clinical use.
The biomarker shows minimal heterogeneity across studies, enhancing its reliability in clinical settings.
Utilizing preoperative serum levels of M2BPGi allows for easy measurement, simplifying monitoring procedures.
A robust association with recurrence risk emphasizes the importance of accurate biomarker detection in managing HCC.

Implication

Observational analysis demonstrates M2BPGi as a biomarker for recurrence in hepatocellular carcinoma, suggesting clinical utility for monitoring.

Abstract

Preoperative serum M2BPGi is a promising biomarker for HCC recurrence after hepatectomy. Its strong association with risk, minimal heterogeneity across studies, and ease of measurement support its potential clinical utility.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stephens et al. (2026) studied this question.

synapsesocial.com/papers/69a75a8bc6e9836116a20808 https://doi.org/10.3748/wjg.v32.i5.113693

View Full Paper

Ask AI

Bookmark

Share

Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading